Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease. MSDC was founded in 2006 by Jerry Colca, PhD and Rolf Kletzien, PhD, former researchers at The Upjohn Company who were among the original researchers in the field of insulin sensitizers, and who selected and led the early development of Actos® (pioglitazone). The company is headquartered in Kalamazoo, Michigan.